Neuronetics, Inc. announced that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar's commitment to simplify the motor threshold determination for physicians. The FDA-cleared technology aids clinicians by visually reporting the magnitude of finger movements during motor threshold (MT) mapping for treatment of major depressive disorder (MDD). D-Tect also allows the MT determination to be performed by only one person.

The D-Tect MT Accessory will initially be available via a limited commercial launch, with a national rollout beginning in mid-September. In addition, practices will be trained on this new product at NeuroStar University, which recently opened in Charlotte, North Carolina. The D-Tect MT Accessory is designed to recognize the movement in three areas of the hand, and it does not require cords or sensors to be attached to the patient.

This streamlines the process compared to the current visual method and provides the clinician with more data, including a comparison of the response to the current versus previous pulse. The D-Tect MT Accessory complements NeuroStar's Fast MT™ and the MT Cap innovations, completing the solution for determining the motor threshold, and delivering an average time savings of 40% for physicians during the MT determination.